AFP
PBYI icon

Ausdal Financial Partners’s Puma Biotechnology PBYI Stock Holding History

Ausdal Financial Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,200
Closed -$94K – 790
2015
Q4 		$94K Buy
+1,200
New +$94.2K 0.05% 328

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ausdal Financial Partners's PBYI Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Puma Biotechnology (PBYI) in Q1 2016, closing a stake of 1,200 shares — an estimated $94K sold.

Ausdal Financial Partners first reported a position in PBYI in Q4 2015 and held it in 1 quarter. The position peaked at $94K in Q4 2015. 119 funds tracked by Wall St. Rank hold PBYI as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Puma Biotechnology position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 1,200 Puma Biotechnology shares in Q1 2016, an estimated $94K.
  • Ausdal Financial Partners first reported a position in Puma Biotechnology in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Puma Biotechnology position peaked at $94K in Q4 2015.
  • 119 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.